Given that many ncRNAs participate in the modulation of EGFR TKI resistance via multiple signaling pathways, ncRNAs potentially serve as therapeutic targets or agents for EGFR TKI-resistant lung cancer [28,33,61,91,103,104,105,106,107,108,109,110,111,112]. The gene discussed is EGFR; the disease is lung carcinoma.